ClinicalTrials.gg
Enrolling by invitationNCT07639853Updated Oct 15, 2026

Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils

An observational study in Arteriovenous Malformation, Gastrointestinal Bleed and Gastric Varices, sponsored by Medtronic Endovascular. Enrolling by invitation at 3 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Medtronic Endovascular (part of Medtronic) · Observational

Updated Oct 15, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 32 studies in Arteriovenous Malformations with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Arteriovenous Malformations · United States.

Planned enrollment
8th of 10
30 · median 110
Started
2026
with 2 others
Observational
10 of 32
4 open now
Registered
31st of 32
by date

Among the 32 studies in Arteriovenous Malformations with a site in United States, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2026, is one of 10 observational ones, and was the 31st registered.

Arteriovenous Malformations

92 studies on the registry are indexed under Arteriovenous Malformations; 29 are open to participants now.

Browse Arteriovenous Malformations studies →

Open to participants now

7 of the 32 studies in Arteriovenous Malformations with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Arteriovenous Malformations studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Arteriovenous Malformations with a site in United States, or all of them as a file.
02

Study summary

The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess clinical safety and performance of the Concerto Versa™ Detachable Coils, when used in accordance with approved device labeling per the Instructions for Use (IFU). Data collected will generate clinical evidence to quantitatively assess clinical safety and device performance for the purpose of obtaining European Union Medical Device Regulation (EU MDR) approval.

Read the detailed description

The Concerto Versa™ Health Care Professional (HCP) Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual use case experience following routine utilization of Concerto Versa™ in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural safety incidents and evaluate device performance. At least 30 use cases will be collected and aggregated from participating HCPs. This data collection is a for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.

03

Conditions studied

  • Arteriovenous Malformation
  • Gastrointestinal Bleed
  • Gastric Varices
  • Hemorrhoid
  • Pelvic Venous Disorders
  • Peripheral Aneurysms
  • Portal Vein Embolization
  • Type II Endoleak
  • Varicocele
  • Hemorrhage

Keywords

  • Peripheral Vascular Disease
  • Vascular Disease
  • Arterial Embolization
  • Arteriovenous Embolization
  • Venous Embolization
  • Embolization Coils
  • Peripheral Embolization Coils
  • Peripheral Arterial Disease
  • Embolization
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The Concerto Versa™ Detachable Coil is indicated for arterial and venous embolization in adult patients requiring embolization in the peripheral vasculature.

Eligibility criteria

Inclusion Criteria:

  1. Patient treated with Concerto Versa™ Detachable Coil is age ≥ 22 years at the time of procedure.
  2. Use of Concerto Versa™ Detachable Coil in accordance with the device labeling.
  3. Reporting of case within 72 hours of index procedure.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients treated with Concerto Versa™ Detachable Coil

    The Concerto Versa™ Detachable Coil is indicated for arterial and venous embolization in adult patients requiring embolization in the peripheral vasculature.

    Device: Concerto Versa™ Detachable Coils

Interventions

  • DeviceConcerto Versa™ Detachable Coils

    Concerto Versa™ detachable coil is indicated for arterial and venous embolization in the peripheral vasculature

06

What researchers measure

Primary outcomes

  1. Rate of peri-procedural adverse events

    The rate of peri-procedural adverse events related to device and/or procedure.

    Time frame: During the Index Procedure

  2. Rate of Technical Success

    Technical success is defined as successful delivery and detachment of the coil, and removal of the delivery-pusher.

    Time frame: During the Index Procedure

Secondary outcomes

  1. Rate of Peri-procedural success

    Peri-procedural success is defined as ability of the device to successfully obstruct or reduce the rate of blood flow to the target lesion as determined by physician judgment.

    Time frame: During the Index Procedure

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 10, 2026
StartActual
Jul 24, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • The Mount Sinai Hospital · New York, United States
  • Rutgers University · Piscataway, United States
across 2 updates, Oct 1, 2026 – Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    1 site added
    Show site
    • Rutgers University · Piscataway, United States
    + 1 other change: verification date
  2. Oct 1, 2026
    1 site added
    Show site
    • The Mount Sinai Hospital · New York, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07639853
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Jul 24, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 15, 2026

Study contacts

John R Laird, Jr, MD
principal investigator · Medtronic Endovascular

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion